Last reviewed · How we verify
Exenatide SC
At a glance
| Generic name | Exenatide SC |
|---|---|
| Also known as | Byetta, exendin-4 |
| Sponsor | Carl T. Hayden VA Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Exenatide for Smoking Cessation and Prevention of Weight Gain (PHASE2)
- Diabetes Islet Preservation Immune Treatment (PHASE1, PHASE2)
- A Trial to Determine the Efficacy and Safety of Presendin in IIH (PHASE3)
- Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM (PHASE4)
- Exenatide for Treating Cocaine Use Disorder (PHASE1, PHASE2)
- Double-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMI (PHASE2)
- A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients (PHASE1)
- Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Exenatide SC CI brief — competitive landscape report
- Exenatide SC updates RSS · CI watch RSS
- Carl T. Hayden VA Medical Center portfolio CI